GlassScriptPhysician profile
Matthew Tanner
NPI 1194380501
$7,311.05
in general payments reported to CMS, 2019-2025
23 companies · $113 in 2025
The $113 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,868 · 2022: $1,782 · 2023: $1,890 · 2024: $1,657 · 2025: $113.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,502 · Education: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,501.97 |
| Education | $158.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,806.37 | 2021-2024 | Enbrel, Tavneos, Otezla |
| Abbvie INC. | $935.04 | 2021-2025 | |
| Janssen Biotech, INC. | $807.03 | 2021-2024 | Tremfya, Remicade, Simponi Aria |
| Astrazeneca Pharmaceuticals LP | $650.47 | 2021-2024 | Saphnelo |
| Lilly USA, LLC | $540.24 | 2021-2024 | Taltz |
| Ucb, INC. | $532.89 | 2021-2024 | Cimzia |
| Novartis Pharmaceuticals Corporation | $518.77 | 2021-2024 | |
| Pfizer INC. | $328.03 | 2021-2024 | |
| Fresenius Kabi USA, LLC | $292.09 | 2023-2024 | Idacio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.83 | 2021-2024 | Cyltezo, Ofev |
| Aurinia Pharma U.S., INC. | $109.30 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $104.52 | 2021-2024 | Orencia |
| Solventum Corporation | $97.55 | 2025 | Activ.A.C. |
| Sandoz INC. | $78.32 | 2023-2024 | Hyrimoz |
| Sobi, INC | $62.10 | 2023-2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $49.86 | 2021-2022 | |
| Glaxosmithkline, LLC. | $44.51 | 2023 | Benlysta |
| Genentech USA, INC. | $38.21 | 2023-2024 | Actemra |
| Genzyme Corporation | $34.78 | 2021-2022 | |
| Organon LLC | $25.12 | 2022-2024 | |
| Radius Health, INC. | $16.23 | 2023 | Tymlos |
| Takeda Pharmaceuticals U.S.A., INC. | $15.10 | 2021 | |
| Idorsia Pharmaceuticals US INC | $11.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Tanner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.